Patent intelligence · US
US 9969742
Imidazotriazinone compounds
Imidazotriazinone compounds
Patent details — US 9969742
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 15, 2018
- Expiration
- May 10, 2038
- Applicant
- IRONWOOD PHARMACEUTICALS, INC.
- Claims
- 3
- CPC classes
- A61P, A61P25/00
Quick answer
US 9969742 (Imidazotriazinone compounds) is held by IRONWOOD PHARMACEUTICALS, INC.. Status: granted. Granted May 15, 2018. Expires May 10, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IRONWOOD PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61P, A61P25/00
More from IRONWOOD PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 10702576
Stable formulations of linaclotide
granted -
US 10675325
Stable formulations of linaclotide
granted -
US 10618938
Compositions for colon cleansing and the treatment of gastrointestinal disorders
granted -
US 10266529
Salts, co-crystals, and polymorphs of an anxiolytic compound
granted -
US 10189809
SGC stimulators
granted -
US 10183021
sGC stimulators
granted -
US 10047095
sGC stimulators
granted
Frequently asked questions
What is US patent 9969742?
US 9969742 (Imidazotriazinone compounds) is held by IRONWOOD PHARMACEUTICALS, INC.. Status: granted. Granted May 15, 2018. Expires May 10, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9969742?
IRONWOOD PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 45 pharmaceutical patents for this assignee.
When does US 9969742 expire?
Our index shows an expiration date of May 10, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.